Clofibrate.

Clofibrate-induced antidiuresis.

Normal subjects and patients with antidiuretic hormone (ADH) deficiency were studied to determine the mechanism of the antidiuretic action of clofibrate. Before clofibrate treatment, the patients' ability to concentrate urine with a standardized dehydration procedure correlated with the amount of ADH which was excreted. During clofibrate administration all six patients with ADH deficiency devel...

Effect of Clofibrate

Intravascular coagulation (IVC) was evaluated in 19 patients with type II and 11 with type IV hyperlipoproteinemia before and after clofibrate therapy by measurement of soluble fibrin complexes (SFC) in plasma; fibrinolysis was estimated by quantitation of fibrin (ogen) degradation products in serum. Untreated type II and type IV patients had increased SFC (P < 0.01). The former also had activa...

Effects of Clofibrate and Sulfinpyrazone

Platelet survival time was measured (autologous labelling with 51chromium) in 68 men with coronary artery disease (CAD). Survival was shortened slightly (3.2 ± 0.04 days; mean ± SEM) as compared to normal (3.7 ± 0.04 days; N = 18; P < 0.001), and 60% had shortened survival (< 3.3 days). Thirty-seven had hyperlipoproteinemia (36 with Type IV and one with Type III) and platelet survival was short...

Clofibrate in chronic simple glaucoma.

The suggestion that clofibrate (Atromid-S; ethyl 2p (chlorophenoxy) -2-methylpropionate) is effective in the treatment of acute angle-closure glaucoma was recently made by Orban, Hanisch, and Vereb (i 966). These authors had previously observed a rise in the concentration offree fatty acids and in blood viscosity just before and during an attack of congestive glaucoma. Although clofibrate effec...

Should clofibrate still be prescribed?